#Norvir

Check out this timeline of the HIV/AIDS in the United States from 1981 to the present.

This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).

Non-alcoholic fatty liver disease can lead to more severe, potentially fatal liver diseases, including cirrhosis.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

A South African study found that this cost-savings measure did not change the likelihood of viral suppression after 48 weeks.

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

The single-tablet antiretroviral regimen includes Janssen’s darunavir plus Gilead’s cobicistat, emtricitabine and tenofovir alafenamide.

This connection remained even when researchers took into account various risk factors for cardiovascular disease.

Most of such drug resistance seen is to older drugs.